Multivariable analysis of SECURE-IBD data demonstrated that increasing age, more than two comorbidities, systemic corticosteroid, and 5-ASA/sulfasalazine used were positively associated with adverse COVID-19 outcomes in IBD patients and the use of immunomodulatory therapy including anti-TNFα antibodies was not associated with risk of morbidity [31]. This evidence concerns the gene TNF and inflammatory bowel disease.